Halozyme Q1 revenue up 21% to $196M; non-GAAP EPS $0.79, net income $76.8M

HALOZYME THERAPEUTICS, INC.

2024-Q1 EPS reported $0.60 revenue$195,879,000

Revenue $195.9M (+21% YoY), driven by 21% royalty growth to $120.6M from DARZALEX and Phesgo.
GAAP diluted EPS $0.60; non-GAAP diluted EPS $0.79, vs $0.29 and $0.47 in Q1 2023.
Adjusted EBITDA $115.7M, up 56% from $74.3M; cash and securities $463.5M at quarter end.
Reiterated FY 2024 guidance: revenue $915-985M, adjusted EBITDA $535-585M, non-GAAP EPS $3.55-$3.90.
New $750M share repurchase program announced; partner milestones include $15M from BMS for nivolumab SC.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

HALOZYME THERAPEUTICS, INC. reported the first quarter ended March 31, 2024 results: revenue $195.9 million, net income $76.8 million. Guidance reaffirmed.

Period: the first quarter ended March 31, 2024
Revenue: $195.9 million
Net income: $76.8 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

any general incorporation language in such filing. --- EX-99.1 (EX-99.1) --- HALOZYME REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATING RESULTS Revenue Increased 21% YOY to $196 million; Net Income of $77 million; Adjusted EBITDA of $116 million; GAAP Diluted EPS of $0.60 and Non-GAAP Diluted EPS of $0.79 1 Royalty Revenue Increased 21% YOY to $121 million

View on SEC.gov

710 earnings releases filed in the last 30 days. Browse all earnings releases →

HALOZYME THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001159036-24-000036

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.